Steven Cohen's NAMS Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 168,901 shares of NewAmsterdam Pharma Company N.V. (NAMS) worth $5.72 M, representing 0.01% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Steven Cohen has initiated a new position in NAMS, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's NewAmsterdam Pharma Company NV (NAMS) Holding Value Over Time
Track share changes against reported price movement
Quarterly NewAmsterdam Pharma Company NV (NAMS) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +168,901 | New Buy | 168,901 | $33.89 |
Steven Cohen's NewAmsterdam Pharma Company NV Investment FAQs
Steven Cohen first purchased NewAmsterdam Pharma Company N.V. (NAMS) in Q2 2026, acquiring 168,901 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held NewAmsterdam Pharma Company N.V. (NAMS) for 1 quarters since Q2 2026.
Steven Cohen's largest addition to NewAmsterdam Pharma Company N.V. (NAMS) was in Q2 2026, adding 168,901 shares worth $5.72 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 168,901 shares of NewAmsterdam Pharma Company N.V. (NAMS), valued at approximately $5.72 M.
As of the Q2 2026 filing, NewAmsterdam Pharma Company N.V. (NAMS) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in NewAmsterdam Pharma Company N.V. (NAMS) was 168,901 shares, as reported at the end of Q2 2026.